ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2781

Assessing RA Disease Activity with Promis Measures Using Smartphone Technology

Huifeng Yun1, Shuo Yang2, W. Benjamin Nowell3, Cooper Filby1, Lang Chen1 and Jeffrey R. Curtis4, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, Outcome measures, PROMIS, rheumatoid arthritis (RA) and technology

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Patient Outcomes, Preferences, and Attitudes II

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and reduce participant burden. The bridge between PROMIS and traditional patient-reported PROs (e.g. RAPID3) is not clear, and it might be possible that some instruments in PROMIS might proxy for measuring more lengthy PROs.

Methods:  Four PROMIS CAT instruments: Pain Interference, Physical Function, Sleep Disturbance, Fatigue, and a visual analog scale (Pain Intensity);and the Routine Assessment of Patient Index Data 3 (RAPID3) were administered to participants in the PCORI-funded ArthritisPower patient registry via a mobile application (App) on their smartphone or computer. The RAPID3 was evaluated in terms of multiple correlations (Pearson) with PROMIS and total variance explained using mixed models. Both the RAPID3 score and category was predicted using the selected 4 PROMIS instruments and pain intensity to form a new predicted score (“CAT-PROMIS RAPID3”). Kappa statistics and Bland-Altman 95% limits of agreement (LOA) were used to measure agreement between the measured RAPID3 and the predicted CAT-PROMIS RAPID3.

Results:  At the time of analysis, 2,376 patients had answered all five PROMIS instruments and the RAPID3 and contributed 3906 observations. Mean +-SD age was 51.6 +/- 10.5 years; 90% were women. Most (81%) had high RAPID3 scores. The mean assessment time for each of the PROMIS instruments ranged from a low of 16 seconds (sleep disturbance) to a high of 105 seconds (RAPID3).As single pairwise comparisons, the 4 PROMIS CATs examined were only modestly correlated (r ~ 0.2-0.4) to one other and the RAPID3. However, in aggregate, the PROMIS instruments explained a very high fraction of total variance (R2=80%) of the RAPID3. The measured RAPID3 was very highly correlated with the CAT-PROMIS predicted RAPID3 (r=0.97). Overall agreement (table) between categories of the RAPID3 vs. CAT-PROMIS RAPID3 also was very high (kappa = 0.81). Bland-Altman 95% limits of agreement shows minimal residual differences and no systematic biases.

Conclusion: There was excellent agreement between the measured RAPID3 and a predicted RAPID3 score estimated using several PROMIS instruments. Few if any questions in the RAPID3 may need to be measured if PROMIS scores are available. 

 

Table. Cross Classification of Patient-reported RAPID3 versus predicted PROMIS-CAT RAPID3

 

PREDICTED CAT-PROMIS RAPID3

RAPID3

Near remission

Low

Moderate

High

Near remission

   34

15

1

0

Low

2

66

45         

0

Moderate

1

6

       423

133

High

0

0

21

3,159

 


Disclosure: H. Yun, BMS, 2; S. Yang, None; W. B. Nowell, Global Healthy Living Foundation, 3; C. Filby, None; L. Chen, None; J. R. Curtis, UCB Pharma, Janssen-Cilag, Amgen, Roche, Myriad Genetics, Lilly, Novartis, BMS, Pfizer, 2,UCB Pharma, Janssen-Cilag, Amgen, Roche, Myriad Genetics, Lilly, Novartis, BMS, Pfizer, 5.

To cite this abstract in AMA style:

Yun H, Yang S, Nowell WB, Filby C, Chen L, Curtis JR. Assessing RA Disease Activity with Promis Measures Using Smartphone Technology [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/assessing-ra-disease-activity-with-promis-measures-using-smartphone-technology/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-ra-disease-activity-with-promis-measures-using-smartphone-technology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology